Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 985.17%.

  • Protagonist Therapeutics' EBITDA Margin fell 984700.0% to 985.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.34%, marking a year-over-year decrease of 381800.0%. This contributed to the annual value of 58.2% for FY2024, which is 2142900.0% up from last year.
  • Protagonist Therapeutics' EBITDA Margin amounted to 985.17% in Q3 2025, which was down 984700.0% from 758.04% recorded in Q2 2025.
  • Protagonist Therapeutics' EBITDA Margin's 5-year high stood at 80.92% during Q1 2024, with a 5-year trough of 4604.78% in Q2 2022.
  • Its 5-year average for EBITDA Margin is 710.36%, with a median of 388.12% in 2021.
  • In the last 5 years, Protagonist Therapeutics' EBITDA Margin crashed by -100797100bps in 2021 and then soared by 3971100bps in 2022.
  • Protagonist Therapeutics' EBITDA Margin (Quarter) stood at 429.57% in 2021, then soared by 92bps to 32.46% in 2022, then skyrocketed by 242bps to 46.1% in 2023, then skyrocketed by 67bps to 76.84% in 2024, then crashed by -1382bps to 985.17% in 2025.
  • Its EBITDA Margin was 985.17% in Q3 2025, compared to 758.04% in Q2 2025 and 68.18% in Q1 2025.